cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Blueprint Medicines Corp
11 own
6 watching
Current Price
$87.43
$-3.2
(-3.53%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
7,157.95M
52-Week High
52-Week High
121.90000
52-Week Low
52-Week Low
72.24000
Average Volume
Average Volume
1.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
17.8934
iconMarket Capitalization7,157.95M
icon52-Week High121.90000
icon52-Week Low72.24000
iconAverage Volume1.3M
iconDividend Yield--
iconP/E Ratio17.8934
What does the Blueprint Medicines Corp do?
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Blueprint Medicines Corp make?
News & Events about Blueprint Medicines Corp.
PR Newswire
1 year ago
Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting PR Newswire CAMBRIDGE, Mass., April 26, 2023 CAMBRIDGE, Mass...
Benzinga
1 year ago
Latest Ratings for BPMC DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform View More Analyst Ratings for BPMC View the Latest Analyst Ratings read more...
Ticker Report
1 year ago
Needham Company LLC reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC Get Rating) in a research report report published on Friday, Benzinga reports. They currently have a $60.00 price target on the biotechnology companys stock. Other analysts have also ...
Zolmax
1 year ago
Blueprint Medicines Co. (NASDAQ:BPMC Get Rating) has been given a consensus recommendation of Moderate Buy by the nineteen analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold ...
Frequently Asked Questions
Frequently Asked Questions
What is Blueprint Medicines Corp share price today?
plus_minus_icon
Can Indians buy Blueprint Medicines Corp shares?
plus_minus_icon
How can I buy Blueprint Medicines Corp shares from India?
plus_minus_icon
Can Fractional shares of Blueprint Medicines Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Blueprint Medicines Corp stocks?
plus_minus_icon
What is today’s traded volume of Blueprint Medicines Corp?
plus_minus_icon
What is today’s market capitalisation of Blueprint Medicines Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Blueprint Medicines Corp?
plus_minus_icon
What percentage is Blueprint Medicines Corp down from its 52-Week High?
plus_minus_icon
What percentage is Blueprint Medicines Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$87.43
$-3.2
(-3.53%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$34.42
$-1.48 (-4.12 %)
MacroGenics, Inc.
MacroGenics, Inc.
$3.18
$-0.17 (-5.07 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$124.79
$-1.48 (-1.17 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$0.88
$-0.10 (-10.48 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$34.42
$-1.48 (-4.12 %)
MacroGenics, Inc.
MacroGenics, Inc.
$3.18
$-0.17 (-5.07 %)
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$124.79
$-1.48 (-1.17 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$0.88
$-0.10 (-10.48 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00